MICHELLE CHMELECKI: Open Payments
NPI 1134456957 · PORTLAND, ME. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$9,536 in 34 payments from 8 companies in 2025. Trend: 2023 $687 · 2024 $538 · 2025 $9,536
Debt forgiveness: $8,709Food & beverage: $827
| Company | Payments | Amount |
|---|---|---|
| Neuronetics, Inc. | 1 | $8,709 |
| ABBVIE INC. | 14 | $382 |
| Otsuka America Pharmaceutical, Inc. | 9 | $221 |
| Axsome Therapeutics, Inc. | 3 | $75 |
| Neurocrine BioSciences, Inc. | 3 | $70 |
| Corium, LLC | 2 | $31 |
| Alkermes, Inc. | 1 | $28 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $19 |
Products named: NEUROSTAR TMS THERAPY SYSTEM, VRAYLAR, REXULTI, Auvelity, INGREZZA, Azstarys, ARISTADA, CAPLYTA.
Industry payments across ME — which companies pay providers there.
